Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Volinanserin (Primary)
- Indications Sleep maintenance insomnia
- Focus Therapeutic Use
- Acronyms NOCTURNE907
- Sponsors Sanofi
- 16 Feb 2009 Actual patient number reported as 604 by ClinicalTrials.gov.
- 16 Feb 2009 Actual end date reported as 1 Jan 2008 by ClinicalTrials.gov.
- 16 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.